Sanofi plans to buy back $152M in Genzyme CVRs

Sanofi ($SNY) plans to buy back up to $152 million in contingent value rights linked to last year's buyout of Genzyme. The French drugmaker says it would purchase about 30% of the CVRs, which pay off if certain Genzyme sales targets are met. The move is seen as a sign that Sanofi is confident that the multiple sclerosis drug Lemtrada will be as lucrative as hoped. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.